Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma - Takeaways - MDSpire

Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma

For patients with relapsed or refractory multiple myeloma (RRMM), the addition of the oral drug mezigdomide to standard treatment with carfilzomib and dexamethasone markedly improved progression-free survival over standard treatment alone, according to results from a phase 3 clinical trial led by investigators at Dana-Farber Cancer Institute.

  • By

  • May 29, 2026

  • 5 min

Share

  • 1

    Mezigdomide significantly improves progression-free survival in relapsed refractory multiple myeloma compared to standard treatment alone.

  • 2

    In the SUCCESSOR-2 trial, patients receiving mezigdomide had a median progression-free survival of 18 months versus 8.3 months for standard treatment.

  • 3

    The majority of patients on mezigdomide (80.2%) responded to treatment, with 26.7% achieving complete response, compared to 53.4% and 8.9% in the standard group.

  • 4

    Mezigdomide has a manageable safety profile, with higher treatment-related side effects (83.7%) than standard treatment (56.5%), but no unexpected adverse effects.

  • 5

    Ongoing studies aim to confirm mezigdomide's effectiveness in combination with other therapies and explore its potential in enhancing immune activity.

Original Source(s)

Addition of Mezigdomide to Standard Therapy Significantly Improves Outcomes in Relapsed Refractory Multiple Myeloma

  • by

  • May 29, 2026

Related Content

Pembrolizumab-associated immune-related hepatitis: a retrospective case report analysis

2026 AACR Renal Cell Carcinoma Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the renal cell carcinoma clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min
The regulatory roles of dysregulated lactate dehydrogenase A in anti-tumor immunity within immune cells